Navigation Links
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
Date:10/23/2008

Details to be presented at NACFC and ICAAC/IDSA meetings this week

SAN DIEGO, Oct. 23 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced additional clinical and preclinical results with MP-376, the company's novel formulation of levofloxacin inhaled solution delivered by an Investigational eFlow Nebulizer System for use in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Clinical results show that aerosol dosing of MP-376 was well tolerated at all dose levels tested after 14 days of dosing. Encouraging signs of drug activity were also observed in this trial. New preclinical results demonstrate that MP-376 has potent activity against Pseudomonas aeruginosa (P. aeruginosa) infection under a wide array of conditions, avoids resistance development when used at high concentrations achievable with aerosol dosing and has anti-inflammatory properties in pulmonary tissues in addition and unrelated to its antibacterial effects. Detailed results are being presented at the North American Cystic Fibrosis Conference (NACFC) and ICAAC/IDSA meetings taking place this week in Orlando, Florida and Washington, D.C., respectively.

Clinical Results

The clinical results being presented at NACFC are from a Phase 1b safety, tolerability and pharmacokinetic (PK) study performed in 40 CF patients with stable disease at 11 U.S. clinical sites (Mpex 203). The study was a placebo-controlled, dose escalation trial to analyze the effects of 14 days of dosing at three different dose levels of MP-376 when administered by inhalation using an Investigational eFlow Nebulizer System.

All patients were required to be culture positive for P. aeruginosa at baseline. P. aeruginosa is a bacterial pathogen that is a leading cause of morbidity in CF patients. The great majority of CF patients over the age of 18 are chronically infected with this pathogen and chronic infection has been shown to lead to acute exacerbations and subsequent loss of l
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Critical Pharmaceuticals Enter Sustained Release hGH Arena
11. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 /CNW/ - More than fifty years ago, ... morning sickness in expectant mothers. Tragically, Thalidomide caused serious and ... Support has been provided to survivors over ... Canada in 1991 and settlements from ... a legal obligation to provide support, we have a clear ...
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist ... Institute recently traveled to Boston, MA ... at the 2015 Heart Rhythm Society conference. These ... to focus on the ideas, people and technology ... Convergent is a hybrid, minimally invasive cardiac operation ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... 1, 2012  PDI, Inc. (Nasdaq: PDII ) ... and full year 2011 financial results on Wednesday, March ... conference call on Thursday, March 8, at 8:30 am ... March 8, 2012Time:8:30 am Eastern timeDial-in numbers:(866) 644-4654 (U.S. ...
... therapies for foot wounds are saving limbs, restoring mobility, ... who suffer from non-healing foot ulcers. "For ... wounds can be a tremendous problem, making these advanced ... clinical professor of surgery at Yale School of Medicine. ...
Cached Medicine Technology:Advanced Treatments Help Hard-to-Heal Diabetic Foot Ulcers—and Improve Lives 2Advanced Treatments Help Hard-to-Heal Diabetic Foot Ulcers—and Improve Lives 3
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on the ... legislature but which has not been signed to date by ... 449 with overwhelming bipartisan support on April 10, 2015, ... This bill ensures that fracking is prohibited in Maryland through ... of fracking to our water supplies and the air we ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... May 22, 2015 Hundreds of ... behalf of individuals who allegedly experienced serious internal ... continue to move forward in the U.S. District ... Pretrial Order dated May 4, 2015, the Court ... and electronically stored information. Among other things, the ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will likely ... pulmonary disorder (COPD) as the dominant companies like ... well as Germany’s Boehringer Ingelheim compete with each ... market payers, clinicians and patients be disposed to ... new ones? , In spite of recently approved ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Other Providers Would Likely Demand Similar,Treatment Next Year, ... released a new ad today warning policymakers,that other Medicare ... the "same prompt-pay deal" next year if Congress requires,pharmacists ... "Paying one group of Medicare providers twice as ...
... Older people are especially,at risk from heat-related health problems such ... currently experiencing, now is not,the time to do chores, run ... for all ages, but potentially life threatening,for older persons," according ... 10 tips for dealing with a heat wave:, 1. ...
... The 125,000-member American College of Physicians (ACP) today ... the Medicare Improvements for Patients and Providers Act of ... S. 3101 because it addresses and incorporates three of ... MD, FACP, wrote Senator Max Baucus (D-MT), chairman of ...
... June 9 Mylan Inc. (NYSE: MYL ),today ... from the U.S. Food and Drug Administration (FDA) for ... mg and 10,mg., Zaleplon Capsules are the generic ... of approximately $88 million for,the 12 months ending March ...
... donates $100,000 to American Red Cross, INDIANAPOLIS, June ... of Eli Lilly and Company (NYSE: LLY ), ... to aid,Indiana tornado and flood victims. More than 44 ... Mitch Daniels as a result of deadly,tornadoes and severe ...
... MADISON, N.J., June 9 Wyeth (NYSE: ... the Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on ... for Wyeth will be Bernard Poussot, President and ... webcast live for investors at, http://www.wyeth.com and ...
Cached Medicine News:Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:How Seniors Can Beat the Heat 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: